Studylog has been featured in such publications as the following:

Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine

Thomas P. Howard, Elaine M. Oberlick, Matthew G. Rees, etc. Clin Cancer Res. 2020 Sep 15; 26(18): 4995–5006.


CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, etc. Nat Commun. 2020; 11: 2641.


The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2

Laetitia Marzi, Yilun Sun, Shar-yin N. Huang, etc. Mol Cancer Ther. 2020 Aug; 19(8): 1589–1597.


Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, etc. Clin Cancer Res. 2020 Sep 1; 26(17): 4633–4642.

Targeting triple-negative breast cancers with the Smac-mimetic birinapant

Najoua Lalaoui, Delphine Merino, Goknur Giner, etc. Cell Death Differ. 2020 Oct; 27(10): 2768–2780.


Combined Targeting of G9a and Checkpoint kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse

Guillermo Urrutia, Ann Salmonson, Jorge Toro-Zapata, etc. Mol Cancer Res. 2020 Mar; 18(3): 448–462.

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Matthew J. Sale, Emma Minihane, Noel R. Monks, etc. Nat Commun. 2019; 10: 5167.


Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation

Mingzhu Wang, Junchao Wang, Rongjuan Wang, etc. Commun Biol. 2019; 2: 392.


Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment

Julie Lang, Anna Capasso, Kimberly R Jordan, etc. J Clin Endocrinol Metab. 2020 Jan; 105(1): 26–42.

Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models

Kai-Liang Zhang, Rui-Ping Li, Bao-Ping Zhang, etc. Onco Targets Ther. 2019; 12: 6515–6523.

Empowering therapeutic antibodies with IFN-α for cancer immunotherapy

Jun Guo, Yu Xiao, Ramesh Iyer, etc. PLoS One. 2019; 14(8): e0219829.

Specific RITA modification produces hyperselective cytotoxicity while maintaining in vivo antitumor efficacy

Brian D. Peyser, Ann Hermone, Joseph M. Salamoun, etc. Mol Cancer Ther. 2019 Oct; 18(10): 1765–1774.


Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates

Jacobi I Cunningham, David J Eyerman, Mark S Todtenkopf, etc. J Psychopharmacol. 2019 Oct; 33(10): 1303–1316.

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)

Holly A. Maulhardt, Lauren Hylle, Michael V. Frost, etc. Cancers (Basel). 2019 Apr; 11(4): 577.

Aryl hydrocarbon receptor acts as a tumor suppressor in a syngeneic MC38 colon carcinoma tumor model

Poonam Yakkundi, Eleanor Gonsalves, Maria Galou-Lameyer, etc. Hypoxia (Auckl). 2019; 7: 1–16.

Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling

Patrick J. Cimino, Lan Huang, Lihua Du, etc. Biomed Rep. 2019 Apr; 10(4): 218–224.